Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Q2 2024 Earnings Conference Call February 8, 2024 4:30 PM ET

Company Participants

Paula Savanti - Head of Investor Relations

Federico Trucco - Chief Executive Officer

Enrique Lopez Lecube - Chief Financial Officer

Conference Call Participants

Delana Kristen-Owen - Oppenheimer

Benjamin Klieve - Lake Street Capital Market

Bobby Burleson - Canaccord

Brian Wright - Roth MKM

Kemp Dolliver - Brookline Capital Markets

Operator

Good afternoon, ladies and gentlemen. Thank you for joining today's Bioceres Crop Solutions Fiscal Second Quarter 2024 Fiscal Results Conference Call. My name is Tia, and I will be your moderator for today's call. All participants’ lines will be muted throughout the presentation. But at the end of the presentation, there will be an opportunity to ask a question. [Operator Instructions]

I would now like to pass the call over to Paula Savanti, Head of Investor Relations at Bioseries Crop Solutions. Please proceed.

Paula Savanti

Good afternoon, and thank you everyone for joining our second quarter Fiscal '24 Earnings Call. Today's presentation will be led by our Chief Executive Officer, Federico Trucco; and our Chief Financial Officer, Enrique Lopez Lecube. Both of them will be available for the Q&A session following the presentation.

Before we proceed, I would like to make the following Safe Harbor Statement. Today’s call will contain forward-looking statements, and I refer you to the forward-looking statements section of today’s earnings release and presentation, as well as the recent filings with the SEC.

We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. This conference call is being webcast, and the webcast link is available at Bioceres Crop Solutions Investor Relations website.

At this time, I will turn the call over to our CEO, Federico Trucco, to begin our presentation

Federico Trucco

Thank you. Thank you, Paula, and thanks, everyone, for joining. Good afternoon or good evening, depending on where you are. It's a pleasure to be having our earnings call today. Please turn to slide number three for this call's highlights. I would like to start by expressing our profound gratitude to our customers, our partners, and the entire Bioseries team from manufacturing to R&D to sales and so on for what has been a new record-setting quarter.

While we are not immune to the broader destocking process in several geographies, resulting in a double-digit contraction in some key markets like Brazil, our portfolio of innovative products, secular growth drivers, and strong execution by our commercial teams allowed us to continue to outperform the industry and deliver our highest quarterly revenues yet.